| Institution: | 1. Johns Hopkins University Whiting School of Engineering, Baltimore, MD, USA;2. Johns Hopkins University School of Medicine, Baltimore, MD, USA;3. Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA;4. InCor Heart Institute, University of São Paulo Medical School, Brazil, São Paulo, Brazil;5. Cardiology Branch, National Heart Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA;6. Charité Medical School-Humboldt, Berlin, Germany;1. Biomedical Instrument Institute, School of Biomedical Engineering, Shanghai Jiao Tong University, Shanghai, China;2. Shanghai Med-X Engineering Research Center, Shanghai Jiao Tong University, Shanghai, China;3. Department of Radiology, The Eighth Affiliated Hospital, Sun Yat-sen University, Shenzhen, China;4. The Lambe Institute for Translational Medicine and Curam, National University of Ireland, Galway, Ireland;5. Department of Radiology, Shanghai Jiao Tong University Affiliated First People''s Hospital, Shanghai, China;6. Department of Radiology, Beijing Anzhen Hospital, Capital Medical University, Beijing, China;7. Department of Cardiovascular Medicine, Wakayama Medical University, Wakayama, Japan;8. Department of Radiology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China;1. The West German Heart and Vascular Center, Department of Cardiology and Vascular Medicine, University Clinic Essen, University of Duisburg-Essen, Essen, Germany;2. The Institute for Diagnostic and Interventional Radiology and Neuroradiology, University Clinic Essen, University of Duisburg-Essen, Essen, Germany;1. Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, UK;2. Department of Cardiology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany;3. Cleveland Clinic Heart and Vascular Institute, Cleveland, OH, USA;4. Cardiology Department, Oxford University Hospitals NHS Foundation Trust, Oxford, UK;5. University College London Institute of Cardiovascular Science, London, UK;6. Oxford Centre of Research Excellence, British Heart Foundation, Oxford, UK;7. Oxford Biomedical Research Centre, National Institute of Health Research, Oxford, UK;8. Clinical Trial Service Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK;9. Caristo Diagnostics, Oxford, UK;1. Department of Cardiology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands;2. Department of Epidemiology and Biostatistics, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands;3. Philips Healthcare, Best, the Netherlands;4. Cleerly, Inc., New York, New York, USA;5. Department of Medicine and Radiology, University of British Columbia, Vancouver, Canada;6. Department of PET Research and Nuclear Medicine, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands;1. Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Faculty of Medicine, Department of Cardiology, Erlangen, Germany;2. Biomedical Imaging Research Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA;3. Monash Cardiovascular Research Centre, Monash University and MonashHeart, Monash Health, Clayton, Victoria, Australia;4. Department of Imaging and Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA |
| Abstract: | BackgroundInflammation surrounding the coronary arteries can be non-invasively assessed using pericoronary adipose tissue attenuation (PCAT). While PCAT holds promise for further risk stratification of patients with low coronary artery disease (CAD) prevalence, its value in higher risk populations remains unknown.MethodsCORE320 enrolled patients referred for invasive coronary angiography with known or suspected CAD. Coronary computed tomography angiography (CCTA) images were collected for 381 patients for whom clinical outcomes were assessed 5 years after enrollment. Using semi-automated image analysis software, PCAT was obtained and normalized for the right coronary (RCA), left anterior descending (LAD), and left circumflex arteries (LCx). The association between PCAT and major adverse cardiovascular events (MACE) during follow up was assessed using Cox regression models.ResultsThirty-seven patients were excluded due to technical failure. For the remaining 344 patients, median age was 62 (interquartile range, 55–68) with 59% having ≥1 coronary artery stenosis of ≥50% by quantitative coronary angiography. Mean attenuation values for PCAT in RCA, LAD, and LCx were ?74.9, ?74.2, and ?71.2, respectively. Hazard ratios and 95% confidence intervals (CI) for normalized PCAT in the RCA, LAD, and LCx for MACE were 0.96 (CI: 0.75–1.22, p ?= ?0.71), 1.31 (95% CI: 0.96–1.78, p ?= ?0.09), and 0.98 (95% CI: 0.78–1.22, p ?= ?0.84), respectively. For death, stroke, or myocardial infarction only, hazard ratios were 0.68 (0.44–1.07), 0.85 (0.56–1.29), and 0.57 (0.41–0.80), respectively.ConclusionsIn patients referred for invasive coronary angiography with suspected CAD, PCAT did not predict MACE during long term follow up. Further studies are needed to understand the relationship of PCAT with CAD risk. |
